(NASDAQ: MYGN), a leader in genetic testing and precision medicine ... These efforts, combined with prudent management of our ...

The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...

SALT LAKE CITY - Myriad Genetics Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine, has announced a strategic partnership with jscreen™, an ...

Myriad develops and offers genetic tests that help assess the risk of developing ... improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Myriad develops and offers genetic tests that help assess the risk of developing ... improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

SALT LAKE CITY - Myriad Genetics Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine, has announced a strategic partnership with jscreen™, an organization ...

Myriad develops and offers genetic tests that help assess the risk of developing ... improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen ...

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...